<html><head><link rel="stylesheet" type="text/css" href="css/style.css"></head><body><div id="main"><h1>Scignal</h1></div> <div class="container"><div class="row"><div class="search"><h2>All Results for : "Nanoparticle delivery" OR "non-viral delivery"</a></h2></div><table><tr><td class="head"><h3>BioRxiv</h3></td><td class="head"><h3>PubMed</h3></td></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Size-Tunable Strategies for a Tumor Targeted Drug Delivery System.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32123729">Link</a></p><p><b>Date:</b> 03/03/2020</p><p><b>Authors:</b> Wenqi Yu ...  Huile Gao</p><p><b>Journal:</b> ACS Cent Sci</p><p><b>IF (7 or above):</b> 9.65</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Nanoparticles have been widely used in tumor targeted drug delivery, while the antitumor effects are not always satisfactory due to the limited penetration and retention.  As we all know, there is a paradox that nanoparticles with large sizes tend to distribute around tumor blood vessels rather than ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: In situ genetic engineering of tumors for long-lasting and systemic immunotherapy.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32034097">Link</a></p><p><b>Date:</b> 02/08/2020</p><p><b>Authors:</b> Stephany Y Tzeng ...  Jordan J Green</p><p><b>Journal:</b> Proc. Natl. Acad. Sci. U.S.A.</p><p><b>IF (7 or above):</b> 9.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Cancer immunotherapy has been the subject of extensive research, but highly effective and broadly applicable methods remain elusive.  Moreover, a general approach to engender endogenous patient-specific cellular therapy, without the need for a priori knowledge of tumor antigen, ex vivo cellular mani ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Chimeric peptide supramolecular nanoparticles for plectin-1 targeted miRNA-9 delivery in pancreatic cancer.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31938057">Link</a></p><p><b>Date:</b> 01/15/2020</p><p><b>Authors:</b> Ying Wu ...  Wei Chen</p><p><b>Journal:</b> Theranostics</p><p><b>IF (7 or above):</b> 8.02</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with poor prognosis.  Insights into the roles of MicroRNAs (miRNAs) in diseases, particularly in cancer, have made miRNAs attractive tools and targets for novel therapeutic approaches.</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32042343">Link</a></p><p><b>Date:</b> 02/11/2020</p><p><b>Authors:</b> Josanne Sophia de Maar ...  Roel Deckers</p><p><b>Journal:</b> Theranostics</p><p><b>IF (7 or above):</b> 8.02</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Genetic and phenotypic tumour heterogeneity is an important cause of therapy resistance.  Moreover, non-uniform spatial drug distribution in cancer treatment may cause pseudo-resistance, meaning that a treatment is ineffective because the drug does not reach its target at sufficient concentrations.</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Nanocarrier-mediated antioxidant delivery for liver diseases.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31938064">Link</a></p><p><b>Date:</b> 01/15/2020</p><p><b>Authors:</b> Senlin Li ...  Lei Zhang</p><p><b>Journal:</b> Theranostics</p><p><b>IF (7 or above):</b> 8.02</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Liver is the principal detoxifying organ and metabolizes various compounds that produce free radicals (FR) constantly.  To maintain the oxidative/antioxidative balance in the liver, antioxidants would scavenge FR by preventing tissue damage through FR formation, scavenging, or by enhancing their dec ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Improving nanotherapy delivery and action through image-guided systems pharmacology.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31938046">Link</a></p><p><b>Date:</b> 01/15/2020</p><p><b>Authors:</b> Thomas S C Ng ...  Miles A Miller</p><p><b>Journal:</b> Theranostics</p><p><b>IF (7 or above):</b> 8.02</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Despite recent advances in the translation of therapeutic nanoparticles (TNPs) into the clinic, the field continues to face challenges in predictably and selectively delivering nanomaterials for the treatment of solid cancers.  The concept of enhanced permeability and retention (EPR) has been coined ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31938067">Link</a></p><p><b>Date:</b> 01/15/2020</p><p><b>Authors:</b> Guillaume Bort ...  Olivier Tillement</p><p><b>Journal:</b> Theranostics</p><p><b>IF (7 or above):</b> 8.02</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Interest of tumor targeting through EPR effect is still controversial due to intrinsic low targeting efficacy and rare translation to human cancers.  Moreover, due to different reasons, it has generally been described for relatively large nanoparticles (NPs) (hydrodynamic diameter > 10 nm).</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31903138">Link</a></p><p><b>Date:</b> 01/06/2020</p><p><b>Authors:</b> Jeroen A C M Goos ...  Thomas P Davis</p><p><b>Journal:</b> Theranostics</p><p><b>IF (7 or above):</b> 8.02</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Expression levels of biomarkers are generally unknown at initial diagnosis.  The development of theranostic probes that do not rely on biomarker availability would expand therapy options for cancer patients, improve patient selection for nanomedicine and facilitate treatment of inoperable patients o ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32089747">Link</a></p><p><b>Date:</b> 02/24/2020</p><p><b>Authors:</b> Henriette S de Bruijn ...  Sabrina Oliveira</p><p><b>Journal:</b> Theranostics</p><p><b>IF (7 or above):</b> 8.02</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Targeted photodynamic therapy (PDT) has the potential to selectively damage tumor tissue and to increase tumor vessel permeability.  Here we characterize the tissue biodistribution of two EGFR-targeted nanobody-photosensitizer conjugates (NB-PS), the monovalent 7D12-PS and the biparatopic 7D12-9G8-P ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: TGF-Î² inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32042344">Link</a></p><p><b>Date:</b> 02/11/2020</p><p><b>Authors:</b> Myrofora Panagi ...  Triantafyllos Stylianopoulos</p><p><b>Journal:</b> Theranostics</p><p><b>IF (7 or above):</b> 8.02</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Tumor normalization strategies aim to improve tumor blood vessel functionality (i. e.</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Nanocarrier-based drug combination therapy for glioblastoma.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31938069">Link</a></p><p><b>Date:</b> 01/15/2020</p><p><b>Authors:</b> Mengnan Zhao ...  Raymond M Schiffelers</p><p><b>Journal:</b> Theranostics</p><p><b>IF (7 or above):</b> 8.02</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The current achievements in treating glioblastoma (GBM) patients are not sufficient because many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem cells, drug efflux pumps and DNA damage repair mechanisms.  Drug combination therapies have shown increasing benefits a ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31998833">Link</a></p><p><b>Date:</b> 01/30/2020</p><p><b>Authors:</b> Jimena G Dancy ...  Anthony J Kim</p><p><b>Journal:</b> Sci Adv</p><p><b>IF (7 or above):</b> 12.53</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Development of effective tumor cell-targeted nanodrug formulations has been quite challenging, as many nanocarriers and targeting moieties exhibit nonspecific binding to cellular, extracellular, and intravascular components.  We have developed a therapeutic nanoparticle formulation approach that bal ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32064335">Link</a></p><p><b>Date:</b> 02/17/2020</p><p><b>Authors:</b> Hongmei Chen ...  Tianmeng Sun</p><p><b>Journal:</b> Sci Adv</p><p><b>IF (7 or above):</b> 12.53</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> CCR9</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: On the design of precision nanomedicines.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32042891">Link</a></p><p><b>Date:</b> 02/11/2020</p><p><b>Authors:</b> Xiaohe Tian ...  Giuseppe Battaglia</p><p><b>Journal:</b> Sci Adv</p><p><b>IF (7 or above):</b> 12.53</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Tight control on the selectivity of nanoparticles' interaction with biological systems is paramount for the development of targeted therapies.  However, the large number of tunable parameters makes it difficult to identify optimal design "sweet spots" without guiding principles.</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Poly(vinyl alcohol) boosting therapeutic potential of </h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32010792">Link</a></p><p><b>Date:</b> 02/05/2020</p><p><b>Authors:</b> Takahiro Nomoto ...  Nobuhiro Nishiyama</p><p><b>Journal:</b> Sci Adv</p><p><b>IF (7 or above):</b> 12.53</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> In the current clinical boron neutron capture therapy (BNCT), </p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32080183">Link</a></p><p><b>Date:</b> 02/22/2020</p><p><b>Authors:</b> Siddharth Patel ...  Gaurav Sahay</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.80</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Endosomal sequestration of lipid-based nanoparticles (LNPs) remains a formidable barrier to delivery.  Herein,Â structure-activity analysis of cholesterol analogues reveals that incorporation of C-24 alkyl phytosterols into LNPs (eLNPs) enhances gene transfection and the length of alkyl tail, flexibi ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32111847">Link</a></p><p><b>Date:</b> 02/29/2020</p><p><b>Authors:</b> Min Li ...  Yucai Wang</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.80</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The efficacy of nano-mediated drug delivery has been impeded by multiple biological barriers such as the mononuclear phagocyte system (MPS), as well as vascular and interstitial barriers.  To overcome the abovementioned obstacles, we report a nano-pathogenoid (NPN) system that can in situ hitchhike  ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Lymphatic endothelial cells prime naÃ¯ve CD8</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31988323">Link</a></p><p><b>Date:</b> 01/28/2020</p><p><b>Authors:</b> Efthymia Vokali ...  Melody A Swartz</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.80</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Lymphatic endothelial cells (LECs) chemoattract naÃ¯ve T cells and promote their survival in the lymph nodes, and can cross-present antigens to naÃ¯ve CD8</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Single AAV-mediated mutation replacement genome editing in limited number of photoreceptors restores vision in mice.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31980606">Link</a></p><p><b>Date:</b> 01/25/2020</p><p><b>Authors:</b> Koji M Nishiguchi ...  Toru Nakazawa</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.80</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Supplementing wildtype copies of functionally defective genes with adeno-associated virus (AAV) is a strategy being explored clinically for various retinal dystrophies.  However, the low cargo limit of this vector allows its use in only a fraction of patients with mutations in relatively small patho ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Roles of circRNAs in the tumour microenvironment.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31973726">Link</a></p><p><b>Date:</b> 01/24/2020</p><p><b>Authors:</b> Qiuge Zhang ...  Zhenqiang Sun</p><p><b>Journal:</b> Mol. Cancer</p><p><b>IF (7 or above):</b> 11.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The tumour microenvironment (TME) constitutes the area surrounding the tumour during its development and has been demonstrated to play roles in cancer-related diseases through crosstalk with tumour cells.  Circular RNAs (circRNAs) are a subpopulation of endogenous noncoding RNAs (ncRNAs) that are ub ....</p></div></td></div></tr></table></div><hr></div></body></html>